International Journal of Cancer Management

Published by: Kowsar

Sensitization of Radio-Resistant Lung Cancer Cells with a B Subunit of Bacterial Cytolethal Distending Toxin from Aggregatibacter actinomycetemcomitans

Hajar Yaghoobi 1 , Bahram Kazemi 2 , 3 and Mojgan Bandehpour 2 , 3 , *
Authors Information
1 Department of Medical Biotechnology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Iranian Journal of Cancer Prevention: February 2017, 10 (2); e5792
  • Published Online: February 18, 2017
  • Article Type: Research Article
  • Received: February 24, 2016
  • Revised: April 24, 2016
  • Accepted: February 11, 2017
  • DOI: 10.5812/ijcp.5792

To Cite: Yaghoobi H, Kazemi B, Bandehpour M. Sensitization of Radio-Resistant Lung Cancer Cells with a B Subunit of Bacterial Cytolethal Distending Toxin from Aggregatibacter actinomycetemcomitans, Int J Cancer Manag. 2017 ; 10(2):e5792. doi: 10.5812/ijcp.5792.

Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. Mol Cancer Ther. 2011; 10(2): 292-302[DOI][PubMed]
  • 2. Connell PP, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009; 69(2): 383-92[DOI][PubMed]
  • 3. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005; 104(6): 1129-37[DOI][PubMed]
  • 4. Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, et al. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5): 458-66[DOI][PubMed]
  • 5. Kaliberov SA, Buchsbaum DJ. Chapter seven--Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res. 2012; 115: 221-63[DOI][PubMed]
  • 6. Rabkin SD, Mineta T, Miyatake S, Yazaki T. Gene therapy: targeting tumor cells for destruction. Hum Cell. 1996; 9(4): 265-76[PubMed]
  • 7. Grasso F, Frisan T. Bacterial Genotoxins: Merging the DNA Damage Response into Infection Biology. Biomolecules. 2015; 5(3): 1762-82[DOI][PubMed]
  • 8. Bezine E, Vignard J, Mirey G. The cytolethal distending toxin effects on Mammalian cells: a DNA damage perspective. Cells. 2014; 3(2): 592-615[DOI][PubMed]
  • 9. Dong JC, Gao H, Zuo SY, Zhang HQ, Zhao G, Sun SL, et al. Neuropilin 1 expression correlates with the Radio-resistance of human non-small-cell lung cancer cells. J Cell Mol Med. 2015; 19(9): 2286-95[DOI][PubMed]
  • 10. Sak A, Wurm R, Elo B, Grehl S, Pottgen C, Stuben G, et al. Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeoxynucleotides targeting p53 and p21(WAF1/CIP1). Cancer Gene Ther. 2003; 10(12): 926-34[DOI][PubMed]
  • 11. Brattstrom D, Bergqvist M, Hesselius P, Wagenius G, Brodin O. Different fraction schedules and combinations with chemotherapy in radiation treatment of non-small cell lung cancer. Anticancer Res. 2000; 20(3B): 2087-90[PubMed]
  • 12. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2): 106-30[DOI][PubMed]
  • 13. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11-30[DOI][PubMed]
  • 14. Hansen HH. Treatment of advanced non-small cell lung cancer. BMJ. 2002; 325(7362): 452-3[DOI][PubMed]
  • 15. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012; 148(1-2): 259-72[DOI][PubMed]
  • 16. Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Inanami O. 8-Aminoadenosine enhances radiation-induced cell death in human lung carcinoma A549 cells. J Radiat Res. 2011; 52(4): 456-63[DOI][PubMed]
  • 17. Iwanaga K, Tominaga K, Yamamoto K, Habu M, Maeda H, Akifusa S, et al. Local delivery system of cytotoxic agents to tumors by focused sonoporation. Cancer Gene Ther. 2007; 14(4): 354-63[DOI][PubMed]
  • 18. Lai CK, Lu YL, Hsieh JT, Tsai SC, Feng CL, Tsai YS, et al. Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy. Nanomedicine (Lond). 2014; 9(6): 803-17[DOI][PubMed]
  • 19. Bachran C, Hasikova R, Leysath CE, Sastalla I, Zhang Y, Fattah RJ, et al. Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins. Cell Death Dis. 2014; 5[DOI][PubMed]
  • 20. Lai CH, Chang CS, Liu HH, Tsai YS, Hsu FM, Yu YL, et al. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. Oncotarget. 2014; 5(14): 5523-34[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments